Literature DB >> 33910876

Treatment of Capecitabine Corneal Side Effects With Autologous Blood-derived Serum Eye Drops.

Federico DI Staso1, Irene Gattazzo2, Beatrice Taurelli Salimbeni3, Alessandro Lambiase4, Gianluca Scuderi2, Silvio DI Staso5, Marco Ciancaglini5.   

Abstract

BACKGROUND/AIM: To describe the clinical progress and management of ocular side effects in a 35-year-old patient with metastatic breast cancer who underwent oral chemotherapy with capecitabine and lapatinib.
MATERIALS AND METHODS: Slit lamp evaluation revealed bilateral perikeratic hyperemia, perilimbal conjunctival edema associated with corneal marginal infiltrates and epithelial and anterior stromal defects in both eyes. Slit lamp examination, in vivo confocal microscopy and anterior-segment optical coherence tomography were highly suggestive for limbal stem cell deficiency. The decision to administer autologous blood- derived serum eye drops was made.
RESULTS: Following administration of autologous blood-derived serum eye drops, corneal marginal infiltrates, epithelial and stromal defects significantly regressed in both eyes after only 10 days. Chemotherapy was resumed and serum eye drops were prescribed simultaneously.
CONCLUSION: Autologous blood-derived serum eye drops may be an adequate therapeutic choice for bilateral corneal lesions detected as ocular side effects of capecitabine. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Capecitabine; autologous serum; breast cancer; chemotherapy; confocal microscopy; cornea; keratitis

Mesh:

Substances:

Year:  2021        PMID: 33910876      PMCID: PMC8193336          DOI: 10.21873/invivo.12451

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  12 in total

1.  Severe ocular irritation and corneal deposits associated with capecitabine use.

Authors:  B Waikhom; F T Fraunfelder; W D Henner; B Walkhom
Journal:  N Engl J Med       Date:  2000-09-07       Impact factor: 91.245

2.  Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization.

Authors:  Mehmet K Kaya; Tamer Demir; Hakan Bulut; Nusret Akpolat; Burak Turgut
Journal:  Clin Exp Ophthalmol       Date:  2015-06-24       Impact factor: 4.207

Review 3.  Lapatinib.

Authors:  Minna Voigtlaender; Tanja Schneider-Merck; Martin Trepel
Journal:  Recent Results Cancer Res       Date:  2018

Review 4.  Capecitabine: a review.

Authors:  Christine M Walko; Celeste Lindley
Journal:  Clin Ther       Date:  2005-01       Impact factor: 3.393

Review 5.  Xeloda in the treatment of metastatic breast cancer.

Authors:  J L Blum
Journal:  Oncology       Date:  1999-07       Impact factor: 2.935

Review 6.  Clinical pharmacokinetics of capecitabine.

Authors:  B Reigner; K Blesch; E Weidekamm
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Histopathologic evidence of capecitabine corneal toxicity in dogs.

Authors:  M Zarfoss; E Bentley; M Milovancev; C Schmiedt; R Dubielzig; J McAnulty
Journal:  Vet Pathol       Date:  2007-09       Impact factor: 2.221

8.  Capecitabine-Induced Bilateral Ectropion: A Rare Ocular Manifestation Requiring Surgical Intervention.

Authors:  Sedat Tatar; Can E Yalçın; Billur Sezgin; Ayşe Y Taş; Orkun Müftüoğlu; Selahattin Özmen
Journal:  J Cutan Aesthet Surg       Date:  2018 Oct-Dec

Review 9.  Blood-Based Treatments for Severe Dry Eye Disease: The Need of a Consensus.

Authors:  Federico Bernabei; Matilde Roda; Marina Buzzi; Marco Pellegrini; Giuseppe Giannaccare; Piera Versura
Journal:  J Clin Med       Date:  2019-09-17       Impact factor: 4.241

10.  Trastuzumab-induced corneal ulceration: successful no-drug treatment of a "blind" side effect in a case report.

Authors:  A Orlandi; R Fasciani; A Cassano; A Agresta; M A Calegari; A Caporossi; C Barone
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.